Tirzepatide
Dual GIP/GLP-1 Agonist
Best For
Clients who have plateaued on other protocols, comprehensive metabolic support
22%
Average body weight reduction
24%
Greater weight loss vs. single-agent therapies
~40%
Reduction in hunger signaling
How It Works
Tirzepatide activates both GIP and GLP-1 receptors simultaneously — two of the three major incretin pathways. This dual mechanism produces superior appetite reduction, improved insulin sensitivity, and enhanced fat oxidation compared to single-pathway agents. The GIP activation appears to independently improve fat metabolism and may contribute to lean mass preservation during weight loss.
Key Research Areas
Appetite Control
Reduces hunger signals by up to 40% through hypothalamic pathways
Fat Loss
Clinical trials show 15-22% total body weight reduction
Blood Sugar
Improves insulin sensitivity and fasting glucose
Cardiovascular
Emerging data shows reduction in heart attacks and stroke risk
Research Highlights
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Formulation Notes
Common concentrations referenced in published clinical studies:
[NV-2010]20mg[NV-2040]40mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.